Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRXNASDAQ:CGONNASDAQ:IDRANASDAQ:KYMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.93+0.2%$9.82$6.00▼$11.31$2.07B1.113.01 million shs2.40 million shsCGONCG Oncology$25.80+0.5%$25.10$14.80▼$40.47$1.96B0.86838,728 shs921,297 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsKYMRKymera Therapeutics$47.14+1.8%$35.90$19.45▼$53.27$3.01B2.07613,053 shs570,077 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+0.20%-0.40%-6.23%+27.31%+58.37%CGONCG Oncology+0.55%-1.68%+1.42%-2.79%-19.12%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%KYMRKymera Therapeutics+1.84%+1.70%+59.85%+55.12%+49.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCRXBioCryst Pharmaceuticals4.328 of 5 stars4.41.00.04.22.41.70.6CGONCG Oncology2.2724 of 5 stars4.51.00.00.02.00.80.0IDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKYMRKymera Therapeutics3.4886 of 5 stars4.53.00.00.03.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5666.72% UpsideCGONCG Oncology 3.00Buy$58.67127.39% UpsideIDRAIdera Pharmaceuticals 0.00N/AN/AN/AKYMRKymera Therapeutics 3.00Buy$59.8226.91% UpsideCurrent Analyst Ratings BreakdownLatest IDRA, KYMR, BCRX, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$52.00 ➝ $56.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.006/2/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$51.005/20/2025KYMRKymera TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/19/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.005/13/2025KYMRKymera TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $70.005/12/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $44.005/12/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M4.61N/AN/A($2.30) per share-4.32CGONCG Oncology$1.14M1,724.98N/AN/A$9.63 per share2.68IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AKYMRKymera Therapeutics$47.07M65.22N/AN/A$12.90 per share3.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.26N/AN/A2.24-10.62%N/A-11.06%8/4/2025 (Estimated)CGONCG Oncology-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AKYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)Latest IDRA, KYMR, BCRX, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CGONCG Oncology-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.932.88CGONCG OncologyN/A30.9730.97IDRAIdera PharmaceuticalsN/A1.561.56KYMRKymera TherapeuticsN/A8.498.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CGONCG Oncology26.56%IDRAIdera Pharmaceuticals12.18%KYMRKymera TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals4.80%CGONCG OncologyN/AIDRAIdera Pharmaceuticals5.05%KYMRKymera Therapeutics16.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.25 million199.21 millionOptionableCGONCG Oncology6176.22 millionN/AOptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableIDRA, KYMR, BCRX, and CGON HeadlinesRecent News About These CompaniesKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by GAMMA Investing LLCJune 23 at 3:10 AM | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by BrokeragesJune 22 at 4:21 AM | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Rhumbline AdvisersJune 18, 2025 | marketbeat.comHarbor Capital Advisors Inc. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)June 14, 2025 | marketbeat.comAnalysts Can't Get Enough of These Little-Known Biopharma StocksJune 12, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)June 8, 2025 | theglobeandmail.comStocks Showing Market Leadership: Kymera Therapeutics Earns 92 RS RatingJune 6, 2025 | msn.comB. Riley Reduces Earnings Estimates for Kymera TherapeuticsJune 6, 2025 | marketbeat.comAmeriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)June 6, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading 6.3% Higher - Here's What HappenedJune 5, 2025 | marketbeat.comLeerink Partnrs Has Bullish Forecast for KYMR Q2 EarningsJune 5, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $311,101.00 in StockJune 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $553,200.00 in StockJune 4, 2025 | marketbeat.comInsider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Sells 30,000 Shares of StockJune 4, 2025 | marketbeat.comBiotech and Social Media Stocks Defy Market Stagnation as Analysts Turn PositiveJune 4, 2025 | investing.comMorgan Stanley Upgrades Kymera Therapeutics (KYMR)June 4, 2025 | msn.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Jeffrey W. Albers Sells 6,349 SharesJune 4, 2025 | insidertrades.comKymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 DegraderJune 4, 2025 | insidermonkey.comKymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to "Buy" RatingJune 3, 2025 | marketbeat.comKymera Soars on Early Protein Degrader DataJune 3, 2025 | biospace.comWhat 6 Analyst Ratings Have To Say About Kymera TherapeuticsJune 3, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksIDRA, KYMR, BCRX, and CGON Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$9.93 +0.02 (+0.20%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.93 0.00 (0.00%) As of 06/24/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.CG Oncology NASDAQ:CGON$25.80 +0.14 (+0.55%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$25.80 0.00 (0.00%) As of 06/24/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Idera Pharmaceuticals NASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Kymera Therapeutics NASDAQ:KYMR$47.14 +0.85 (+1.84%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$46.85 -0.29 (-0.62%) As of 06/24/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
